Skip to Main Content Skip to Site Map Skip to Accessibility Statement

Recommend Technology Appraisals

Service notifications for recommended Technology Appraisals (TAs)

Technology Appraisals are listed below in alphanumerical order with links to further information on the NICE website.

TitleDescriptionDate addedDownload
TA544

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma

14-02-0001 DownloadPreview
TA531

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (review of TA447)

20-11-0007 DownloadPreview
TA252-TA253

http://guidance.nice.org.uk/ta253

20-05-2013 DownloadPreview
TA238

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis

20-05-2013 DownloadPreview
TA236

Ticagrelor for acute coronary syndromes

20-05-2013 DownloadPreview
TA235

Mifamurtide for the treatment of osteosarcoma

03-10-2014 DownloadPreview
TA343-TA344

Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic joint with untreated chronic lymphocytic leukaemia (joint with TA344)

13-10-2015 DownloadPreview
TA335

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

13-10-2015 DownloadPreview
TA342

Vedolizumab for treating moderately to severely active ulcerative colitis

15-10-2015 DownloadPreview
TA370

Ciclosporin for treating dry eye disease which has not improved after treatment with artificial tears.

25-04-2016 DownloadPreview
TA374

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy

06-05-2016 DownloadPreview
TA377

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.

16-06-2016 DownloadPreview
TA375

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

16-06-2016 DownloadPreview
TA373

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35)

16-06-2016 DownloadPreview
TA376

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases

16-06-2016 DownloadPreview
TA383

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (including a review of TA143 and TA233).

16-06-2016 DownloadPreview
TA381

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy.

16-06-2016 DownloadPreview
TA380

Panobinostat for treating multiple myeloma after at least 2 previous treatments.

16-06-2016 DownloadPreview
TA379

Nintedanib for treating idiopathic pulmonary fibrosis

16-06-2016 DownloadPreview
TA375

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35)

16-06-2016 DownloadPreview
1 2 3 17
NICE Ref Title Date Issued by HSCB
TA234 Abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor 05/01/2012
TA233 Golimumab for the treatment of ankylosing spondylitis 20/02/2012
TA232 Retigabine for the adjunctive treatment of partial onset seizures in epilepsy 05/01/2012
TA230 Bivalirudin for the treatment of ST-segment-elevation myocardial infarction 05/01/2012
TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion 05/01/2012
TA228 Bortezomib and thalidomide for the firstline treatment of multiple myeloma 05/01/2012
TA227 Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer 05/01/2012
TA226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma 05/01/2012
TA225 Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti- rheumatic drugs 20/02/2012
TA223 Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease 05/01/2012
TA222 Trabectedin for the treatment of relapsed ovarian cancer 05/01/2012
TA221 Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura 05/01/2012
TA220 Golimumab for the treatment of psoriatic arthritis 20/02/2012
TA216 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia 05/01/2012
TA215 Pazopanib for the first-line treatment of advanced renal cell carcinoma 05/01/2012
TA208 Trastuzumab for the treatment of HER2-positive metastatic gastric cancer 05/01/2012
TA203 Liraglutide for the treatment of type 2 diabetes mellitus 20/02/2012
TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C 05/01/2012
TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis 20/02/2012
TA198 Tocilizumab for the treatment of rheumatoid arthritis 05/01/2012
TA197 Dronedarone for the treatment of non-permanent atrial fibrillation 20/02/2012
TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor 05/01/2012
TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia 05/01/2012
TA190 Pemetrexed for the maintenance treatment of non-small-cell lung cancer 05/01/2012
TA188 Human growth hormone (somatropin) for the treatment of growth failure in children 05/01/2012
TA187 Infliximab (review) and adalimumab for the treatment of Crohn’s disease 05/01/2012
TA186 Certolizumab pegol for the treatment of rheumatoid arthritis 20/02/2012
TA169 Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma 05/01/2012
TA166 Cochlear implants for children and adults with severe to profound deafness 05/01/2012
TA98 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents 14/09/2016
TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C 05/01/2012
TA23 Temozolomide for the treatment of recurrent malignant gliomaC 02/08/2016
TA20 Riluzole for the treatment of Motor Neurone Disease 01/08/2016